Cargando…

Low-level viraemia during treatment with darunavir/r monotherapy versus DRV/r + 2NRTIs in the MONET trial

Detalles Bibliográficos
Autores principales:	Clumeck, N, Arribas, JR, Pulick, P, Fätkenheuer, G, Hill, A, Van Delft, Y, Moecklinghoff, C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The International AIDS Society 2010
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112831/ http://dx.doi.org/10.1186/1758-2652-13-S4-O19

Ejemplares similares

Analysis of major and minor IAS-USA PI mutations in the MONET trial of darunavir/ritonavir monotherapy versus DRV/r + 2NRTIs
por: Pulido, F, et al.
Publicado: (2010)

The MONET trial: correlation between Hepatitis C coinfection and HIV RNA responses during darunavir/ritonavir monotherapy, for patients with HIV RNA <50 copies/mL at baseline
por: Arribas, Jose R, et al.
Publicado: (2010)

Analysis of BENCHMRK 1 & 2 using PhenoSense® assay for darunavir (DRV/r) resistance and exploration of functional monotherapy with RAL vs DRV
por: Rockstroh, J, et al.
Publicado: (2010)

No Difference in the Rate of Change in Telomere Length or Telomerase Activity in HIV-Infected Patients after Three Years of Darunavir/Ritonavir with and without Nucleoside Analogues in the MONET Trial
por: Solomon, Ajantha, et al.
Publicado: (2014)

Effectiveness and durability of darunavir/ritonavir (DRV/r) in DRV/r-experienced HIV-1-infected patients in routine clinical practice
por: Antinori, Andrea, et al.
Publicado: (2014)

Safety of darunavir/ritonavir (DRV/r) in HIV-1-infected DRV/r-experienced and -naïve patients: analysis of data in the real-world setting in Italy
por: Antinori, Andrea, et al.
Publicado: (2014)

First-line therapy with LPV/r vs NVP and 2 NRTIs in a developing country: W144 of a randomized trial
por: Clumeck, Nathan, et al.
Publicado: (2014)

The PROTEA trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV-1 RNA below 50 copies/mL
por: Antinori, Andrea, et al.
Publicado: (2014)

Pharmacokinetic (PK) and pharmacodynamic analyses of once- and twice-daily darunavir/ritonavir (DRV/r) in the ODIN trial
por: Sekar, V, et al.
Publicado: (2010)

The clinical development of NRTIs — cautionary tales
por: Cooper, D
Publicado: (2010)

Health-related quality of life (HRQoL) assessment with once- and twice-daily darunavir/ritonavir (DRV/r) in the ODIN trial
por: Spinosa-Guzman, S, et al.
Publicado: (2010)

Influence of demographic and disease parameters on virological response to once- vs twice-daily darunavir/ritonavir (DRV/r) at week 48 in ODIN
por: Sension, M, et al.
Publicado: (2010)

ARTEMIS: 192-week efficacy and safety of once-daily darunavir/ritonavir (DRV/r) vs lopinavir/r (LPV/r) in treatment-naïve HIV-1-infected adults
por: Orkin, C, et al.
Publicado: (2010)

The state of PI monotherapy and NRTI-sparing therapy
por: Arribas, JR
Publicado: (2010)

Cost-efficacy analysis of the MONET trial using Spanish antiretroviral drug prices
por: Arribas, JR, et al.
Publicado: (2010)

Randomized trial of DRV/r or LPV/r QD monotherapy vs maintaining a PI/r-based antiretroviral regimen in persons with suppressed HIV replication
por: Pinnetti, Carmela, et al.
Publicado: (2014)

Mechanism of Darunavir (DRV)’s High Genetic Barrier to HIV-1 Resistance: A Key V32I Substitution in Protease Rarely Occurs, but Once It Occurs, It Predisposes HIV-1 To Develop DRV Resistance
por: Aoki, Manabu, et al.
Publicado: (2018)

Changing prevalence of darunavir resistance-associated mutations (DRV RAMs) in clinical samples received for routine resistance testing: 2003-2009
por: De La Rosa, G, et al.
Publicado: (2010)

DRV concentrations and viral load in CSF in patients on DRV/r 600/100 or 800/100mg once daily plus two NRTI
por: Di Yacovo, Silvana, et al.
Publicado: (2014)

543. An Integrated Safety Analysis Comparing Once-Daily Doravirine (DOR) to Darunavir+Ritonavir (DRV+r) and Efavirenz (EFV) in HIV-1-Infected, Antiretroviral Therapy (ART)-Naïve Adults
por: Thompson, Melanie, et al.
Publicado: (2018)

HIV-2 gene product-specific T cell responses and viraemia control
por: Leligdowicz, Aleksandra, et al.
Publicado: (2006)

Low level viraemia and the risk of virological failure in HIV infected patients
por: Florea, Dragoş, et al.
Publicado: (2014)

Analysis of neurocognitive function and CNS endpoints in the PROTEA trial: darunavir/ritonavir with or without nucleoside analogues
por: Clarke, Amanda, et al.
Publicado: (2014)

Darunavir/cobicistat showing similar effectiveness as darunavir/ritonavir monotherapy despite lower trough concentrations
por: Gutierrez‐Valencia, Alicia, et al.
Publicado: (2018)

Monet : 1840-1926.
por: Monet, Claude, 1840-1926
Publicado: (1994)

In Vitro and Ex Vivo Inhibition of Human Telomerase by Anti-HIV Nucleoside Reverse Transcriptase Inhibitors (NRTIs) but Not by Non-NRTIs
por: Hukezalie, Kyle R., et al.
Publicado: (2012)

Monet at Giverny /
por: Sagner-Düchting, Karin
Publicado: (1999)

Monetizing Innovation
por: Ramanujam, Madhavan
Publicado: (2016)

Claude Monet
por: Levine, Steven Z.
Publicado: (1994)

Claude Monet /
por: Tobien, Felicitas
Publicado: (2017)

Monet and Cataracts
por: Hajar, Rachel
Publicado: (2016)

Monotherapy with darunavir/ritonavir is effective and safe in clinical practice
por: Pasquau, Juan, et al.
Publicado: (2014)

An association between K65R and HIV-1 subtype C viruses in patients treated with multiple NRTIs
por: Smit, Erasmus, et al.
Publicado: (2017)

Phase IIIb, open-label single-arm trial of darunavir/cobicistat (DRV/COBI): Week 48 subgroup analysis of HIV-1-infected treatment-nave adults
por: Tashima, Karen, et al.
Publicado: (2014)

Third‐line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource‐limited settings: ACTG A5288 strategy trial
por: Avihingsanon, Anchalee, et al.
Publicado: (2022)

Effectiveness of a reduced dose of efavirenz plus 2 NRTIs as maintenance antiretroviral therapy with the guidance of therapeutic drug monitoring
por: Yang, Shang-Ping, et al.
Publicado: (2014)

Darunavir pharmacokinetics throughout pregnancy and postpartum
por: Lambert, John, et al.
Publicado: (2014)

How to monetize your data
por: Wixom, Barbara Haley, et al.
Publicado: (2017)

Claude Monet, 1840-1926
por: Heinrich, Christoph
Publicado: (2000)

An observational comparison of first-line combination antiretroviral treatment (cART) with 2NRTI and ATV/r or DRV/r in HIV-infected patients in Italy
por: Cozzi-Lepri, Alessandro, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_3jodg4oj2d8iugl8mp21v41ah5